Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastické činidlá - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline trading services limited, Írsko - flutikazón - 14 - bronchodilatantia, antiasthmatica

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline trading services limited, Írsko - flutikazón - 14 - bronchodilatantia, antiasthmatica

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline trading services limited, Írsko - flutikazón - 14 - bronchodilatantia, antiasthmatica

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline trading services limited, Írsko - salmeterol - 14 - bronchodilatantia, antiasthmatica

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline trading services limited, Írsko - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline trading services limited, Írsko - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

glaxosmithkline trading services limited, Írsko - salmeterol a flutikazón - 14 - bronchodilatantia, antiasthmatica

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pozri časti 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostatné dermatologické prípravky - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.